Orexo AB (ORX) - Total Assets

Latest as of June 2026: Skr514.60 Million SEK ≈ $55.38 Million USD

Based on the latest financial reports, Orexo AB (ORX) holds total assets worth Skr514.60 Million SEK (≈ $55.38 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Orexo AB - Total Assets Trend (2002–2025)

This chart illustrates how Orexo AB's total assets have evolved over time, based on quarterly financial data. Also see market value of Orexo AB for the company's overall valuation and market capitalisation.

Orexo AB - Asset Composition Analysis

Current Asset Composition (December 2025)

Orexo AB's total assets of Skr514.60 Million consist of 89.4% current assets and 10.6% non-current assets. Review Orexo AB (ORX) total liabilities to assess the company's total debt and financial obligations.

Asset Category	Amount (SEK)	% of Total Assets
Cash & Equivalents	Skr0.00	70.0%
Accounts Receivable	Skr228.30 Million	17.5%
Inventory	Skr0.00	0.0%
Property, Plant & Equipment	Skr56.40 Million	4.3%
Intangible Assets	Skr400.00K	0.0%
Goodwill	Skr0.00	0.0%

Asset Composition Trend (2002–2025)

This chart illustrates how Orexo AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Orexo AB stock quote for real-time trading data and today's change.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Orexo AB's current assets represent 89.4% of total assets in 2025, an increase from 61.1% in 2002.
Cash Position: Cash and equivalents constituted 70.0% of total assets in 2025, up from 44.7% in 2002.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 29.0% in 2002.
Asset Diversification: The largest asset category is accounts receivable at 17.5% of total assets.

Orexo AB Competitors by Total Assets

Key competitors of Orexo AB based on total assets are shown below.

Company	Country	Total Assets
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Sweden	Skr81.26 Billion
Yunnan Baiyao Group Co Ltd SHE:000538	China	CN¥53.34 Billion
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	China	CN¥5.17 Billion
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	USA	$15.42 Trillion
Harbin Gloria Pharmaceuticals SHE:002437	China	CN¥3.14 Billion
Jiuzhitang Co Ltd SHE:000989	China	CN¥5.73 Billion
Renhe Pharmacy Co Ltd SHE:000650	China	CN¥7.93 Billion
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	China	CN¥6.74 Billion

Orexo AB - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.65	1.48	2.50
Quick Ratio	1.65	1.32	2.24
Cash Ratio	0.00	0.00	0.00
Working Capital	Skr149.90 Million	Skr120.50 Million	Skr536.30 Million

Orexo AB - Advanced Valuation Insights

This section examines the relationship between Orexo AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	1.86
Latest Market Cap to Assets Ratio	0.04
Asset Growth Rate (YoY)	119.0%
Total Assets	Skr1.30 Billion
Market Capitalization	$48.39 Million USD

Valuation Analysis

Below Book Valuation: The market values Orexo AB's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Orexo AB's assets grew by 119.0% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Orexo AB (2002–2025)

The table below shows the annual total assets of Orexo AB from 2002 to 2025.

Year	Total Assets	Change
2025-12-31	Skr1.30 Billion ≈ $140.20 Million	+119.03%
2024-12-31	Skr594.80 Million ≈ $64.01 Million	-24.38%
2023-12-31	Skr786.60 Million ≈ $84.65 Million	-29.07%
2022-12-31	Skr1.11 Billion ≈ $119.35 Million	-12.93%
2021-12-31	Skr1.27 Billion ≈ $137.07 Million	+3.31%
2020-12-31	Skr1.23 Billion ≈ $132.68 Million	-17.87%
2019-12-31	Skr1.50 Billion ≈ $161.54 Million	+16.66%
2018-12-31	Skr1.29 Billion ≈ $138.47 Million	+28.17%
2017-12-31	Skr1.00 Billion ≈ $108.04 Million	-1.46%
2016-12-31	Skr1.02 Billion ≈ $109.64 Million	+0.25%
2015-12-31	Skr1.02 Billion ≈ $109.37 Million	-17.10%
2014-12-31	Skr1.23 Billion ≈ $131.92 Million	+58.73%
2013-12-31	Skr772.33 Million ≈ $83.12 Million	+60.32%
2012-12-31	Skr481.75 Million ≈ $51.84 Million	-11.78%
2011-12-31	Skr546.10 Million ≈ $58.77 Million	-23.37%
2010-12-31	Skr712.69 Million ≈ $76.70 Million	+9.76%
2009-12-31	Skr649.33 Million ≈ $69.88 Million	-7.51%
2008-12-31	Skr702.02 Million ≈ $75.55 Million	-12.45%
2007-12-31	Skr801.87 Million ≈ $86.29 Million	+111.06%
2006-12-31	Skr379.93 Million ≈ $40.89 Million	+2.32%
2005-12-31	Skr371.31 Million ≈ $39.96 Million	+250.24%
2004-12-31	Skr106.02 Million ≈ $11.41 Million	+134.80%
2003-12-31	Skr45.15 Million ≈ $4.86 Million	+35.80%
2002-12-31	Skr33.25 Million ≈ $3.58 Million	--

About Orexo AB

ST:ORX Sweden Drug Manufacturers - Specialty & Generic

Market Cap

$48.39 Million

Skr449.63 Million SEK

Market Cap Rank

#22110 Global

#410 in Sweden

Share Price

Skr12.80

Change (1 day)

-0.31%

52-Week Range

Skr12.74 - Skr41.60

All Time High

Skr85.70